FDA clears GE's Clariscan macrocyclic GBCA

2019 02 05 17 15 4430 Ge Rsna 2018 400

GE Healthcare has received U.S. Food and Drug Administration (FDA) clearance for use of the company's Clariscan macrocyclic gadolinium-based contrast agent (GBCA) with MRI scans.

Previously introduced at ECR 2017 in Vienna, the Clariscan contrast agent is designed to improve visualization of the blood-brain barrier and vascular abnormalities in the brain, spine, and related tissues of adult and pediatric patients.

GE has received approval for Clariscan in more than 55 countries, the company said.

Page 1 of 604
Next Page